Results 181 to 190 of about 472,072 (313)
Research Progress of Puerarin and Its Benefits in Nonalcoholic Fatty Liver Disease: A Bibliometric Analysis. [PDF]
Wang W, Liu X.
europepmc +1 more source
Hepatocytes are subjected to increased membrane tension along with lipid accumulation. Loss of PIEZO1 exacerbates high‐fat diet‐induced MASLD in mice. Activation of PIEZO1 alleviates high‐fat diet‐induced MASLD in mice. PIEZO1 negatively regulates de novo lipogenesis through activation of CaMKK2‐AMPK pathway. ABSTRACT Liver is a central organ for lipid
Hui Chen +14 more
wiley +1 more source
Clinical efficacy of PPAR agonists in the treatment of nonalcoholic fatty liver disease. [PDF]
Li X, Zhang J, Wei B, Tong H.
europepmc +1 more source
Adipocyte‐Derived Leptolin Enhances Energy Expenditure and Prevents Obesity
We identified a novel adipokine, which we named leptolin. In humans, leptolin levels in white adipose tissue were positively correlated with exercise and negatively associated with body mass index. We observed elevated leptolin in serum from athletes and lower leptolin in serum from obese individuals.
Jiarui Liu +17 more
wiley +1 more source
Association of Euthyroid Thyroid Hormone Levels with Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease. [PDF]
Oral A +5 more
europepmc +1 more source
PET Imaging of Cardiac Inflammation in Viral Myocarditis Using a DPP4‐Targeted Probe
This study describes a DPP4‐targeted PET probe for imaging myocardial inflammation by selectively targeting activated immune cells. Derived from the clinically approved small‐molecule inhibitor linagliptin, the probe demonstrates favorable biodistribution with specific cardiac uptake in myocarditis.
Wanhao Gao +14 more
wiley +1 more source
Roles of mitochondrial complexes in non-alcoholic fatty liver disease. [PDF]
Wang K, Wang L, Ning J, Li D.
europepmc +1 more source

